Moreover, Leslie et al. reported that endometrial carcinoma cells harboring p53-null mutation are much more sensitive to the combinatorial treatment with gefitinib and paclitaxel than those harboring wild-type p53 or hotspot mutants38,39. The gene discussed is TP53; the disease is endometrial carcinoma.